EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
[HTML][HTML] EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
J Hou, H Li, S Ma, Z He, S Yang, L Hao, H Zhou… - Biomarker …, 2022 - Springer
Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …
discovery of epidermal growth factor receptor (EGFR) gene mutations and the development …
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
GJ Riely, JW Neal, DR Camidge, AI Spira, Z Piotrowska… - Cancer discovery, 2021 - AACR
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
gene mutations, including exon 20 insertions (EGFR ex20ins), in non–small cell lung …
[PDF][PDF] Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The …
Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: a phase 1 …
C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - jamanetwork.com
Importance Metastatic non–small cell lung cancer (mNSCLC) withEGFRexon 20 insertion
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Epidermal growth factor receptor exon 20 insertion mutations (EGFR exon20ins) are
detected in approximately 2% of patients with non–small cell lung cancer (NSCLC). Due to a …
detected in approximately 2% of patients with non–small cell lung cancer (NSCLC). Due to a …
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions
NJ Choudhury, AJ Schoenfeld, J Flynn, CJ Falcon… - Clinical Cancer …, 2021 - AACR
Purpose: EGFR exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell
lung cancer (NSCLC) for which targeted therapies are under development. We sought to …
lung cancer (NSCLC) for which targeted therapies are under development. We sought to …
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: From mechanism analysis to clinical strategy
Y Zhao, H Wang, C He - Journal of Cancer Research and Clinical …, 2021 - Springer
Purpose Non-small cell lung cancer (NSCLC) accounts for about 85% in all cases of lung
cancer. In recent years, molecular targeting drugs for NSCLC have been developed rapidly …
cancer. In recent years, molecular targeting drugs for NSCLC have been developed rapidly …
Targeting acquired and intrinsic resistance mechanisms in epidermal growth factor receptor mutant non-small-cell lung cancer
MP Shah, JW Neal - Drugs, 2022 - Springer
Over the past 2 decades, rapid advances in molecular profiling and the development of
targeted therapies have dramatically improved the clinical course of advanced non-small …
targeted therapies have dramatically improved the clinical course of advanced non-small …
Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations
GJ Yang, J Li, HY Xu, Y Sun, L Liu, HS Li, L Yang… - Lung Cancer, 2021 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20 ins) mutations
are generally associated with de novo resistance to first-or second-generation EGFR …
are generally associated with de novo resistance to first-or second-generation EGFR …